Literature DB >> 12973380

Dexmedetomidine.

J Mantz1.   

Abstract

Pharmacological manipulation of the sympathetic tone has led to the synthesis of novel compounds to control stress-induced hemodynamic disorders. The use of alpha(2)-adrenoceptor agonists is particularly interesting in this regard, since these agents decrease sympathetic activity by reducing norepinephrine release from nerve terminals. Dexmedetomidine is a potent, highly selective alpha(2)-adrenoceptor agonist. Its use is associated with a decrease in heart rate and blood pressure both in animals and humans. Several lines of evidence suggest that this compound increases perioperative cardiovascular stability and reduces the incidence of ischemic episodes in patients with coronary artery disease. In addition to its cardiovascular properties, dexmedetomidine possesses anxiolytic, hypnotic/sedative, anesthetic-sparing and analgesic actions and is devoid of significant respiratory depressant effects. Targeted mutations of the alpha(2) receptor site indicate that the alpha(2A) subtype is primarily involved in its sedative and anesthetic-sparing effects. Because of these properties, dexmedetomidine may be particularly useful during the perioperative period, as well as for sedation of patients in critical care settings. (c) 1999 Prous Science. All rights reserved.

Entities:  

Year:  1999        PMID: 12973380     DOI: 10.1358/dot.1999.35.3.533844

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  12 in total

1.  The effects of intravenous dexmedetomidine on spinal hyperbaric ropivacaine anesthesia.

Authors:  Kamuran Elcicek; Murat Tekin; Ismail Kati
Journal:  J Anesth       Date:  2010-05-14       Impact factor: 2.078

2.  Dexmedetomidine.

Authors:  N Bhana; K L Goa; K J McClellan
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

3.  Is the addition of dexmedetomidine to a ketamine-propofol combination in pediatric cardiac catheterization sedation useful?

Authors:  Ayşe Ülgey; Recep Aksu; Cihangir Bicer; Aynur Akin; Resul Altuntaş; Aliye Esmaoğlu; Ali Baykan; Adem Boyaci
Journal:  Pediatr Cardiol       Date:  2012-02-16       Impact factor: 1.655

4.  Dexmedetomidine in the supratentorial craniotomy.

Authors:  Osman Ilhan; Senem Koruk; Gokcen Serin; Ibrahim Erkutlu; Unsal Oner
Journal:  Eurasian J Med       Date:  2010-08

Review 5.  Dexmedetomidine: a review of applications for cardiac surgery during perioperative period.

Authors:  Xiaoyu Zhang; Xuan Zhao; Yingwei Wang
Journal:  J Anesth       Date:  2014-06-10       Impact factor: 2.078

6.  Comparison of Intravenous Dexmedetomidine with Midazolam in Prolonging Spinal Anaesthesia with Ropivacaine.

Authors:  Balwinder Kaur Rekhi; Tejinderpal Kaur; Divya Arora; Pankaj Dugg
Journal:  J Clin Diagn Res       Date:  2017-02-01

7.  Effect of Dexmedetomidine IV on the Duration of Spinal Anesthesia with Prilocaine: A Double-Blind, Prospective Study in Adult Surgical Patients.

Authors:  Murat Tekin; Ismail Kati; Yakup Tomak; Erol Kisli
Journal:  Curr Ther Res Clin Exp       Date:  2007-09

8.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

9.  Dexmedetomidine for sedation of patients undergoing elective surgery under regional anesthesia.

Authors:  Jia Song; Woong-Mo Kim; Seong-Heon Lee; Myung Ha Yoon
Journal:  Korean J Anesthesiol       Date:  2013-09-25

10.  Ineffective doses of dexmedetomidine potentiates the antinociception induced by morphine and fentanyl in acute pain model.

Authors:  Mumin Unal; Sinan Gursoy; Ahmet Altun; Cevdet Duger; Iclal Ozdemir Kol; Kenan Kaygusuz; Ihsan Bagcivan; Caner Mimaroglu
Journal:  Korean J Physiol Pharmacol       Date:  2013-10-17       Impact factor: 2.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.